Prognostic Significance of Preoperative ¹⁸F-FDG PET/CT in Uterine Leiomyosarcoma

Overview

Journal J Gynecol Oncol

Specialties Gynecology & Obstetrics
Oncology

Date 2017 Apr 7

PMID 28382795

Citations 7

Authors

Jeong Yeol Park

Jeong Won Lee

Hyun Ju Lee

Jong Jin Lee

Seung Hwan Moon

Seo Young Kang

Gi Jeong Cheon

Hyun Hoon Chung

Affiliations

Soon will be listed here.

Abstract

Objective: Uterine leiomyosarcoma (LMS) is a rare and aggressive disease with poor outcome. Due to its rarity and conflict of data, investigation on finding prognostic factor is challenging. The aim of the study was to investigate the prognostic significance of preoperative ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) in uterine LMS.

Methods: This was a retrospective observational cohort study in 3 tertiary referral hospitals. We retrospectively evaluated data from patients with pathologically proven uterine LMS who underwent preoperative ¹⁸F-FDG PET/CT scans at 3 institutions. The prognostic implication of PET/CT parameters and other clinico-pathological parameters on disease-free survival (DFS) and overall survival (OS) was evaluated.

Results: Clinico-patholgical data were reviewed for 19 eligible patients. In the group overall, median DFS and OS were 12 and 20 months, respectively. As for the recurrence, large tumor size, and high tumor maximum standardized uptake value (SUVmax) were demonstrated as risk factors of recurrence. As for the OS, high tumor SUVmax was demonstrated as the unique risk factor. There were significant differences in tumor size, mitotic count, SUVmax, and DFS between patients with and without recurrence. Also, there were significant differences in tumor size, SUVmax, DFS, and OS between 2 subgroups stratified by cut-off SUVmax.

Conclusion: SUVmax at preoperative ¹⁸F-FDG PET/CT was associated with worse outcome in patients with uterine LMS. In the preoperative setting, SUVmax can be a valuable non-invasive prognostic marker. Additionally, SUVmax can help identify highly aggressive uterine LMS and may help in adjusting standard treatment toward an individualized, risk-adapted treatment.

Citing Articles

Bladder leiomyoma and the utility of F-Fluorodeoxyglucose-Positron Emission Tomography - a Case Report.

Lim K, Morkos K, Levy S, Davis P Bladder (San Franc). 2023; 10:e21200003.

PMID: 37936581 PMC: 10627076. DOI: 10.14440/bladder.2023.859.

Metastatic Pattern of Truncal and Extremity Leiomyosarcoma: Retrospective Analysis of Predictors, Outcomes, and Detection.

Tigchelaar S, Frey C, Sivaraj D, Segovia N, Mohler D, Steffner R J Pers Med. 2022; 12(3).

PMID: 35330345 PMC: 8949223. DOI: 10.3390/jpm12030345.

Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma.

Tolwani A, Matusiak M, Bui N, Forgo E, Varma S, Baratto L NPJ Genom Med. 2021; 6(1):30.

PMID: 33941787 PMC: 8093268. DOI: 10.1038/s41525-021-00193-w.

Differentiating uterine sarcoma from leiomyoma: BETTER Check!.

Smith J, Zawaideh J, Sahin H, Freeman S, Bolton H, Addley H Br J Radiol. 2021; 94(1125):20201332.

PMID: 33684303 PMC: 9327746. DOI: 10.1259/bjr.20201332.

Presurgical Identification of Uterine Smooth Muscle Malignancies through the Characteristic FDG Uptake Pattern on PET Scans.

Ho K, Fang Y, Lin G, Ueng S, Wu T, Lai C Contrast Media Mol Imaging. 2018; 2018:7890241.

PMID: 30018513 PMC: 6029472. DOI: 10.1155/2018/7890241.

References

Giuntoli 2nd R, Metzinger D, DiMarco C, Cha S, Sloan J, Keeney G . Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003; 89(3):460-9. DOI: 10.1016/s0090-8258(03)00137-9. View

Kapp D, Shin J, Chan J . Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008; 112(4):820-30. DOI: 10.1002/cncr.23245. View

Leitao Jr M, Zivanovic O, Chi D, Hensley M, OCearbhaill R, Soslow R . Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol. 2012; 125(2):409-13. DOI: 10.1016/j.ygyno.2012.02.014. View

Gadducci A, Cosio S, Romanini A, Genazzani A . The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2007; 65(2):129-42. DOI: 10.1016/j.critrevonc.2007.06.011. View

Major F, Blessing J, Silverberg S, Morrow C, Creasman W, Currie J . Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993; 71(4 Suppl):1702-9. DOI: 10.1002/cncr.2820710440. View

Yorulmaz G, Erdogan G, Pestereli H, Savas B, Karaveli F . Epithelioid leiomyosarcoma with rhabdoid features. Wien Klin Wochenschr. 2007; 119(17-18):557-60. DOI: 10.1007/s00508-007-0822-3. View

Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I . Endometrial cancer. Lancet. 2005; 366(9484):491-505. DOI: 10.1016/S0140-6736(05)67063-8. View

Hanley J, McNeil B . The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143(1):29-36. DOI: 10.1148/radiology.143.1.7063747. View

Gadducci A, Landoni F, Sartori E, Zola P, Maggino T, Lissoni A . Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol. 1996; 62(1):25-32. DOI: 10.1006/gyno.1996.0185. View

10.

Schwartz L, Diamond M, Schwartz P . Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol. 1993; 168(1 Pt 1):180-3. DOI: 10.1016/s0002-9378(12)90910-2. View

11.

Metz C . Basic principles of ROC analysis. Semin Nucl Med. 1978; 8(4):283-98. DOI: 10.1016/s0001-2998(78)80014-2. View

12.

Hensley M, Barrette B, Baumann K, Gaffney D, Hamilton A, Kim J . Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S61-6. PMC: 4830912. DOI: 10.1097/IGC.0000000000000261. View

13.

Eary J, OSullivan F, Powitan Y, Chandhury K, Vernon C, Bruckner J . Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2002; 29(9):1149-54. DOI: 10.1007/s00259-002-0859-5. View

14.

Folpe A, Lyles R, Sprouse J, Conrad 3rd E, Eary J . (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000; 6(4):1279-87. View

15.

Eary J, Conrad E, Bruckner J, Folpe A, Hunt K, Mankoff D . Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res. 1998; 4(5):1215-20. View

16.

Brenner W, Eary J, Hwang W, Vernon C, Conrad E . Risk assessment in liposarcoma patients based on FDG PET imaging. Eur J Nucl Med Mol Imaging. 2006; 33(11):1290-5. DOI: 10.1007/s00259-006-0170-y. View

17.

Toro J, Travis L, Wu H, Zhu K, Fletcher C, Devesa S . Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer. 2006; 119(12):2922-30. DOI: 10.1002/ijc.22239. View

18.

Siedhoff M, Kim K . Morcellation and myomas: Balancing decisions around minimally invasive treatments for fibroids. J Surg Oncol. 2016; 112(7):769-71. DOI: 10.1002/jso.24010. View

19.

Brooks S, Zhan M, Cote T, Baquet C . Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004; 93(1):204-8. DOI: 10.1016/j.ygyno.2003.12.029. View

20.

Zivanovic O, Leitao M, Iasonos A, Jacks L, Zhou Q, Abu-Rustum N . Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol. 2009; 27(12):2066-72. PMC: 3646302. DOI: 10.1200/JCO.2008.19.8366. View